European stocks opened lower, mirroring last week's decline, with travel and media sectors lagging. Novo Nordisk rebounded ...

Investing.com -- Novo Nordisk (CSE:NOVOb) shares jumped over 9% on Monday, despite the company’s disappointing results for ...

This comes after the drugmaker's disappointing results for experimental obesity drug CagriSema wiped out as much as $125 ...

ASX narrowly avoids disaster after CHESS glitch, with CBA and consumer stocks bouncing back, iron ore slipping.

The pharmaceutical industry faces significant challenges as Novo Nordisk and Eli Lilly grapple with trial setbacks and market ...

Novo Nordisk (NVO) increased valuation gap with Eli Lilly (LLY) after its Phase 3 data for next-gen weight loss drug ...

Second, the company could make significant clinical progress next year. Novo Nordisk has several late-stage programs in ...

Evan David Seigerman, BMO managing director, joins 'Fast Money' to discuss Novo sinking on its obesity drug data.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...

The U.S. Food and Drug Administration declined to approve Lexicon Pharmaceuticals' add-on drug for type 1 diabetes and chronic kidney disease, the company said on Friday.